In the adjuvant setting, trials like TREAT-CTC (EORTC 90091-10093) investigated the role of trastuzumab in HER2 non-amplified early breast cancer with circulating tumor cells, but it was stopped for futility, highlighting the complexity and the need for molecular characterization of CTCs [5]. Here, ERBB2 is linked to breast cancer.